2005
Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction
Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. Circulation 2005, 111: 3411-3419. PMID: 15967846, DOI: 10.1161/circulationaha.104.508093.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug Therapy, CombinationElectrocardiographyFemaleHeart VentriclesHospitalizationHumansHypertrophy, Left VentricularMaleMiddle AgedMyocardial InfarctionPrognosisStroke VolumeTetrazolesTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsAngiotensin receptor blockersMyocardial infarctionEjection fractionEchocardiographic measuresPo bidPo tidHeart failureTreatment armsInfarct segment lengthProgressive LV enlargementVALIANT Echo studyLV ejection fractionLeft ventricular enlargementCombination of captoprilACE inhibitor captoprilEnd-diastolic volumeARB valsartanEchocardiographic characteristicsVALIANT studyCardiovascular eventsEchocardiographic parametersLV dysfunctionReceptor blockersLV enlargementVentricular enlargement
2000
Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers M, Velazquez E, Califf R, Investigators* F. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal 2000, 140: 727-750. PMID: 11054617, DOI: 10.1067/mhj.2000.108832.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilCause of DeathDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHumansMulticenter Studies as TopicMyocardial InfarctionOdds RatioPatient SelectionProportional Hazards ModelsRandomized Controlled Trials as TopicResearch DesignSample SizeTetrazolesValineValsartanConceptsAngiotensin II receptor blockersII receptor blockersAcute myocardial infarctionMyocardial infarctionReceptor blockersVentricular dysfunctionHeart failureAngiotensin II receptor blocker valsartanEnzyme inhibitorsMajor nonfatal cardiovascular eventsAcute Myocardial Infarction trialAngiotensin-converting enzyme inhibitorDose of captoprilMultiple practice patternsNonfatal cardiovascular eventsUse of valsartanMyocardial Infarction trialReceptor blocker valsartanHigh-risk patientsLeft ventricular dysfunctionParallel-group studyRenin-angiotensin systemManagement of patientsCombination of captoprilLong-term treatment